



PHARMA



Press release |

IBA OPENS A NEW RADIOPHARMACEUTICALS PRODUCTION CENTER IN BRUSSELS

Embargo until 5:40 p.m. (Belgian time) – May 10, 2007

Louvain-la-Neuve, Belgium, May 10, 2007 – IBA (Ion Beam Applications S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) announced today the inauguration of its production site for radiopharmaceutical products in Brussels, Belgium. This new site named BetaPlus Pharma is a joint-venture between IBA and the Cliniques universitaires Saint-Luc. The site has begun distribution of Positron Emission Tomography (PET) radiopharmaceuticals, mainly FDG (Fluorodeoxyglucose). These radiopharmaceutical agents are designed for use in Molecular Imaging, the latest and most precise technique used to detect oncological, cardiological and neurological diseases. It is the first production site for radiopharmaceuticals that IBA operates in Belgium.

An inauguration ceremony took place in Brussels this afternoon in the presence of Bernard Coulie, Rector of the Université catholique de Louvain and the management of IBA.

This new facility is the latest addition to the IBA distribution network, which includes 35 PET radiopharmaceuticals production centers across the world. Thanks to its central location, the Brussels facility entitles IBA to supply PET radiopharmaceuticals to Belgium, North of France and Holland. Supply in this very active area will be strengthened by IBA in the coming months, with the opening of an additional facility in Gent, Belgium and the beginning of production in Fleurus, Belgium by 2008.

“The opening of this new center, in one of Europe’s most populated zone, reinforces the position of IBA as the largest radiopharmaceuticals distribution network in Europe. IBA remains committed to developing the most advanced and complete PET radiopharmaceuticals distribution network throughout the world. We are proud and excited to develop presence in these areas where availability and reliability of supply is from now on guaranteed”, said Pierre Mottet, Chief Executive Officer of IBA. “In every country where IBA operates, we are committed to support the development of PET diagnostics through reliable supply of FDG”, Pierre Mottet added.



PHARMA

Press release |

ABOUT IBA

IBA delivers solutions of a unique precision in the fields of **cancer diagnosis and therapy**. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

IBA is organized into two sectors of business:

- The Production and Distribution of Radioisotopes which covers the production and distribution of radiopharmaceutical tracers used in medical imaging, the main one being FDG (F-18 Fluorodeoxyglucose);
- The Technology & Equipment sector which forms the technological basis for a number of the company's activities and covers the development, manufacturing, marketing and services linked to the equipment, including particle accelerators, for imaging, therapy, dosimetry or sterilization and ionization.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Phone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com

